BioSpace

BioSpace is a digital hub for life science news and jobs, providing essential insights and tools to connect innovative organizations with talented professionals who work towards advancing health and quality of life globally. The platform offers various resources for companies to make informed decisions regarding their workforce. With a relationship with two-thirds of the entire U.S. life science workforce, BioSpace has a rapidly growing subscriber list and over 12,000 new site registrations every month.

100%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This news site is known for its high journalistic standards. It strives to maintain neutrality and transparency in its reporting, and avoids conflicts of interest. It has a reputation for accuracy and rarely gets contradicted on major discrepancies in its reporting.

Bias

100%

Examples:

No current examples available.

Conflicts of Interest

100%

Examples:

No current examples available.

Contradictions

95%

Examples:

  • Patients treated with Mounjaro were more likely to achieve meaningful weight loss than those on Ozempic.

Deceptions

100%

Examples:

No current examples available.

Recent Articles

  • Mounjaro Outperforms Ozempic in Weight Loss: Study Finds 7% Greater Average Loss After One Year

    Mounjaro Outperforms Ozempic in Weight Loss: Study Finds 7% Greater Average Loss After One Year

    Broke On: Tuesday, 09 July 2024 In a JAMA Internal Medicine study, researchers compared outcomes of over 18,000 US patients on Eli Lilly's Mounjaro (tirzepatide) and Novo Nordisk's Ozempic (semaglutide), finding that Mounjaro led to greater weight loss with 81.8% vs. 66.5% achieving five percent or more weight loss, and an average seven percent greater weight loss at twelve months.